229 related articles for article (PubMed ID: 28762388)
21. Updates to the Management of Kidney Cancer.
Jonasch E
J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
[TBL] [Abstract][Full Text] [Related]
22. Novel targeted therapy for advanced renal carcinoma: trials in progress.
Calabrò F; Sternberg CN
Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
[TBL] [Abstract][Full Text] [Related]
23. Management of locally advanced renal cell carcinoma.
Rodriguez A; Sexton WJ
Cancer Control; 2006 Jul; 13(3):199-210. PubMed ID: 16885916
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
Bandini M; Smith A; Marchioni M; Pompe RS; Martel TF; Cindolo L; Montorsi F; Shariat SF; Briganti A; Kapoor A; Capitanio U; Karakiewicz PI
Clin Genitourin Cancer; 2018 Jun; 16(3):176-183. PubMed ID: 29449091
[TBL] [Abstract][Full Text] [Related]
25. Concomitant intraoperative renal artery embolization and resection of complex renal carcinoma.
Lin PH; Terramani TT; Bush RL; Keane TE; Moore RG; Lumsden AB
J Vasc Surg; 2003 Sep; 38(3):446-50. PubMed ID: 12947251
[TBL] [Abstract][Full Text] [Related]
26. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
Bex A; Horenblas S; de Gast GC
Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma.
Naito S; Kimiya K; Sakamoto N; Soejima T; Ueda T; Kumazawa J; Osada Y; Kurozumi T; Sagiyama K; Ariyoshi A
Urology; 1991 Feb; 37(2):95-9. PubMed ID: 1992596
[TBL] [Abstract][Full Text] [Related]
28. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
29. Kidney Cancer: An Overview of Current Therapeutic Approaches.
Chowdhury N; Drake CG
Urol Clin North Am; 2020 Nov; 47(4):419-431. PubMed ID: 33008493
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.
Subramanian P; Haas NB
Urol Oncol; 2018 Jan; 36(1):23-30. PubMed ID: 29051029
[TBL] [Abstract][Full Text] [Related]
31. Testicular metastasis from renal cell carcinoma after nephrectomy and on tyrosine kinase inhibitors therapy: Case report and review.
De Gobbi A; Mangano MS; Cova G; Lamon C; Maccatrozzo L
Urologia; 2019 May; 86(2):96-98. PubMed ID: 30706765
[TBL] [Abstract][Full Text] [Related]
32. Outcome assessment of patients with metastatic renal cell carcinoma under systemic therapy using artificial neural networks.
Buchner A; Kendlbacher M; Nuhn P; Tüllmann C; Haseke N; Stief CG; Staehler M
Clin Genitourin Cancer; 2012 Mar; 10(1):37-42. PubMed ID: 22056212
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?
Patel DN; Figlin RA; Kim HL
Clin Adv Hematol Oncol; 2016 Nov; 14(11):907-914. PubMed ID: 27930642
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy after nephrectomy for renal cell carcinoma.
Ravaud A
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
36. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
[TBL] [Abstract][Full Text] [Related]
38. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
39. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
40. The Evolution of Nephrectomy and Patient Characteristics in Metastatic Renal Cell Carcinoma Patients Enrolled Into First-Line Tyrosine Kinase Inhibitors Clinical Trials.
Sella A; Wang K; Sella T
Clin Genitourin Cancer; 2016 Oct; 14(5):415-419. PubMed ID: 27105724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
